ATE419036T1 - Verbesserung der aktivität der inselzellen bei diabetes mellitus und dessen prävention - Google Patents

Verbesserung der aktivität der inselzellen bei diabetes mellitus und dessen prävention

Info

Publication number: ATE419036T1
Authority: AT; Austria
Prior art keywords: cells; insulin producing; pancreatic; prevention; diabetes mellitus
Prior art date: 2000-03-31

Application number

AT01927848T

Other languages

English (en)

Inventor

Hans-Ulrich Demuth

Konrad Glund

Original Assignee

Prosidion Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-31

Filing date

2001-04-02

Publication date

2009-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22716142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE419036(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-02 Application filed by Prosidion Ltd filed Critical Prosidion Ltd

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE419036T1 publication Critical patent/ATE419036T1/de

Links

206010012601 diabetes mellitus Diseases 0.000 title 1
230000002265 prevention Effects 0.000 title 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 6
102000004877 Insulin Human genes 0.000 abstract 3
108090001061 Insulin Proteins 0.000 abstract 3
229940125396 insulin Drugs 0.000 abstract 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 2
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
230000004069 differentiation Effects 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
210000002919 epithelial cell Anatomy 0.000 abstract 1
230000002641 glycemic effect Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000012423 maintenance Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
210000004923 pancreatic tissue Anatomy 0.000 abstract 1
230000004962 physiological condition Effects 0.000 abstract 1
230000008929 regeneration Effects 0.000 abstract 1
238000011069 regeneration method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Immunology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Hematology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Orthopedic Medicine & Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)
Enzymes And Modification Thereof (AREA)

AT01927848T 2000-03-31 2001-04-02 Verbesserung der aktivität der inselzellen bei diabetes mellitus und dessen prävention ATE419036T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US19406100P	2000-03-31	2000-03-31

Publications (1)

Publication Number	Publication Date
ATE419036T1 true ATE419036T1 (de)	2009-01-15

Family

ID=22716142

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01927848T ATE419036T1 (de)	2000-03-31	2001-04-02	Verbesserung der aktivität der inselzellen bei diabetes mellitus und dessen prävention

Country Status (21)

Country	Link
US (5)	US6500804B2 (de)
EP (3)	EP2055302B1 (de)
JP (1)	JP2003528135A (de)
KR (2)	KR20080067009A (de)
CN (2)	CN101690815A (de)
AT (1)	ATE419036T1 (de)
AU (2)	AU2001254763A1 (de)
BR (1)	BR0109553A (de)
CA (1)	CA2400226C (de)
CY (1)	CY1108872T1 (de)
CZ (1)	CZ20023234A3 (de)
DE (1)	DE60137216D1 (de)
DK (2)	DK2055302T3 (de)
ES (3)	ES2320630T5 (de)
HU (1)	HU229042B1 (de)
IL (1)	IL151368A0 (de)
NO (1)	NO20024643L (de)
PT (3)	PT2055302E (de)
RU (1)	RU2261096C2 (de)
WO (1)	WO2001072290A2 (de)
ZA (1)	ZA200206460B (de)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020006899A1 (en) *	1998-10-06	2002-01-17	Pospisilik Andrew J.	Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
ATE357509T1 (de)	1997-09-29	2007-04-15	Point Therapeutics Inc	Stimulierung von hämatopoietischen zellen im vitro
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) *	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6979697B1 (en) *	1998-08-21	2005-12-27	Point Therapeutics, Inc.	Regulation of substrate activity
US20030176357A1 (en) *	1998-10-06	2003-09-18	Pospisilik Andrew J.	Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US6890904B1 (en)	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
DE19940130A1 (de) *	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US20030040469A1 (en) *	2000-03-08	2003-02-27	Knudsen Liselotte Bjerre	Lowering serum lipids
KR20080067009A (ko) *	2000-03-31	2008-07-17	프로시디온 리미티드	디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
CA2424475A1 (en) *	2000-10-27	2002-05-02	Probiodrug Ag	Method for the treatment of neurological and neuropsychological disorders
US20030022816A1 (en) *	2001-03-07	2003-01-30	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US6890905B2 (en) *	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention
US20070293426A1 (en) *	2001-04-02	2007-12-20	Hans-Ulrich Demuth	Methods for improving islet signaling in diabetes mellitus and for its prevention
GB0109146D0 (en) *	2001-04-11	2001-05-30	Ferring Bv	Treatment of type 2 diabetes
US20030130199A1 (en) *	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
CN1723196A (zh)	2001-06-27	2006-01-18	史密丝克莱恩比彻姆公司	作为二肽酶抑制剂的氟代吡咯烷
US7368421B2 (en) *	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
EP1492525A2 (de) *	2001-08-16	2005-01-05	Probiodrug AG	Verwendung von hemmern der prolin endopeptidase zur veränderung der inositol-1,4,5-triphosphatkonzentration die von intrazellularen signalkaskaden abhängt
US6844316B2 (en) *	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
WO2003045228A2 (en) *	2001-11-26	2003-06-05	Trustees Of Tufts College	Methods for treating autoimmune disorders, and reagents related thereto
CA2479812A1 (en) *	2002-02-28	2003-09-04	Prosidion Ltd.	Glutaminyl based dpiv inhibitors
US20030232761A1 (en) *	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
DE60329724D1 (de)	2002-06-07	2009-11-26	Waratah Pharmaceuticals Inc	Methoden und Kompositionen um Diabetes zu behandeln
ES2306781T3 (es) *	2002-08-09	2008-11-16	Prosidion Ltd.	Inhibidores de la dipeptidil-peptidasa iv para disminucion de la tasa de aumento cronico de peso.
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003262059A1 (en) *	2002-09-11	2004-04-30	Takeda Pharmaceutical Company Limited	Sustained release preparation
ATE461212T1 (de) *	2002-09-18	2010-04-15	Prosidion Ltd	Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv)
US20040058876A1 (en) *	2002-09-18	2004-03-25	Torsten Hoffmann	Secondary binding site of dipeptidyl peptidase IV (DP IV)
AU2003283004A1 (en) *	2002-10-22	2004-05-13	Waratah Pharmaceuticals, Inc.	Treatment of diabetes
DE10308352A1 (de)	2003-02-27	2004-09-09	Aventis Pharma Deutschland Gmbh	Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en)	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308351A1 (de)	2003-02-27	2004-11-25	Aventis Pharma Deutschland Gmbh	1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de)	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de)	2003-02-27	2004-12-23	Aventis Pharma Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
CA2518465A1 (en) *	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2004098591A2 (en) *	2003-05-05	2004-11-18	Probiodrug Ag	Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
EP1961416B1 (de) *	2003-05-05	2013-01-23	Probiodrug AG	Verwendung von Hemmern von Glutaminylcyclase zur Behandlung von Rheumatoider Arthritis, Psoriasis oder Atherosklerose
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
EP1699777B1 (de)	2003-09-08	2012-12-12	Takeda Pharmaceutical Company Limited	Dipeptidylpeptidase-hemmer
EP1697342A2 (de) *	2003-09-08	2006-09-06	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitoren
BRPI0415409A (pt) *	2003-10-15	2006-12-05	Probiodrug Ag	uso de efetuadores de ciclases de glutaminila e glutamato
ES2231036B1 (es) *	2003-10-31	2006-07-01	Encofrados J. Alsina, S.A.	Puntal.
US20050171112A1 (en) *	2003-11-03	2005-08-04	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
US20100099721A1 (en) *	2003-11-03	2010-04-22	Probiodrug Ag	Novel compounds for the treatment of neurological disorders
WO2005049022A2 (en)	2003-11-17	2005-06-02	Novartis Ag	Use of dipeptidyl peptidase iv inhibitors
RU2766487C2 (ru)	2004-01-20	2022-03-15	Новартис Аг	Композиция и способ прямого прессования
US7241787B2 (en) *	2004-01-25	2007-07-10	Sanofi-Aventis Deutschland Gmbh	Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
CA2554809C (en)	2004-02-05	2014-04-29	Probiodrug Ag	Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
AU2005216970B2 (en) *	2004-02-23	2011-07-07	Trustees Of Tufts College	Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
UA85871C2 (uk)	2004-03-15	2009-03-10	Такеда Фармасьютікал Компані Лімітед	Інгібітори дипептидилпептидази
DE602004004631D1 (de)	2004-04-01	2007-03-22	Sanofi Aventis Deutschland	Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
US7687638B2 (en)	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7842707B2 (en)	2004-07-23	2010-11-30	Nuada, Llc	Peptidase inhibitors
US20070259927A1 (en) *	2004-08-26	2007-11-08	Takeda Pharmaceutical Company Limited	Remedy for Diabetes
US20060063719A1 (en) *	2004-09-21	2006-03-23	Point Therapeutics, Inc.	Methods for treating diabetes
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008524331A (ja)	2004-12-21	2008-07-10	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤
KR20080000665A (ko)	2005-04-22	2008-01-02	알란토스 파마슈티컬즈 홀딩, 인코포레이티드	디펩티딜 펩티다아제-ⅳ 억제제
DE102005026762A1 (de)	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
MY152185A (en)	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20090202497A1 (en) *	2005-08-23	2009-08-13	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
PE20070622A1 (es) *	2005-09-14	2007-08-22	Takeda Pharmaceutical	Administracion de inhibidores de dipeptidil peptidasa
MY147393A (en) *	2005-09-14	2012-11-30	Takeda Pharmaceutical	Administration of dipeptidyl peptidase inhibitors
PT1931350E (pt) *	2005-09-14	2014-02-12	Takeda Pharmaceutical	Administração de inibidores de dipeptidil peptidase
TW200745080A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CA2623826A1 (en) *	2005-09-30	2007-04-12	Novartis Ag	Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
CN101365476A (zh) *	2005-10-07	2009-02-11	瓦拉塔药品公司	Dpp-iv抑制剂和胃泌素化合物的联合使用
AT502717A1 (de) *	2005-11-09	2007-05-15	Omnica Gmbh	Pharmazeutische verwendung einer verbindung
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2007112368A1 (en) *	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Preparation of (r)-3-aminopiperidine dihydrochloride
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP2540725A1 (de)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
MX2009002772A (es) *	2006-09-13	2009-05-28	Takeda Pharmaceutical	Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro- 2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo.
TW200838536A (en) *	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
US20080293644A1 (en) *	2007-04-27	2008-11-27	Thomas Eidenberger	Guava extract
WO2009024542A2 (en) *	2007-08-17	2009-02-26	Boehringer Ingelheim International Gmbh	Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ604091A (en) *	2008-08-15	2014-08-29	Boehringer Ingelheim Int	Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh)	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US9144205B2 (en)	2008-10-17	2015-09-29	Alchem Environmental Ip Llc	Hydroponics applications and ancillary modifications to a polyphasic pressurized homogenizer
US9757683B1 (en)	2008-10-17	2017-09-12	Alchem Environmental Ip Llc	Polyphasic pressurized homogenizer (PPH) and methods for methane purification
US8241410B1 (en)	2008-10-17	2012-08-14	Alchem Environmental LLC	Ancillary embodiments and modifications to a polyphasic pressurized homogenizer
CN102256976A (zh)	2008-12-23	2011-11-23	贝林格尔.英格海姆国际有限公司	有机化合物的盐形式
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
WO2010108144A1 (en) *	2009-03-19	2010-09-23	Georgia Tech Research Corporation	Systems and methods for improved wireless interface aggregation
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
WO2011161161A1 (en)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Diabetes therapy
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102807568B (zh) *	2011-05-31	2015-11-25	正大天晴药业集团股份有限公司	噻二唑衍生物类dpp-iv抑制剂
US8883800B2 (en)	2011-07-15	2014-11-11	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (de)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medizinische verwendung eines dpp-4-inhibitors
CN105315301B (zh) *	2014-08-05	2018-04-03	连云港润众制药有限公司	噻二唑类dpp‑ⅳ抑制剂的枸橼酸盐
EA201791982A1 (ru)	2015-03-09	2020-02-17	Интекрин Терапьютикс, Инк.	Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
CN106620704A (zh) *	2016-11-04	2017-05-10	广州赛莱拉干细胞科技股份有限公司	一种治疗糖尿病的制剂及其制备方法和应用
WO2018162722A1 (en)	2017-03-09	2018-09-13	Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke	Dpp-4 inhibitors for use in treating bone fractures
JP2020515639A (ja)	2017-04-03	2020-05-28	コヒラス・バイオサイエンシズ・インコーポレイテッド	進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
CN112386217A (zh) *	2019-08-14	2021-02-23	关永晖	一种膀胱镜注射针

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2961377A (en)	1957-08-05	1960-11-22	Us Vitamin Pharm Corp	Oral anti-diabetic compositions and methods
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
DE2009743A1 (de)	1970-03-03	1971-09-16	Farbenfabriken Bayer Ag, 5090 Leverkusen	Substituierte Biguanide mit antihyperglykämischer Wirkung
US3879541A (en) *	1970-03-03	1975-04-22	Bayer Ag	Antihyperglycemic methods and compositions
US3960949A (en)	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
CH602612A5 (de) *	1974-10-11	1978-07-31	Hoffmann La Roche
US4935493A (en)	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
US5433955A (en)	1989-01-23	1995-07-18	Akzo N.V.	Site specific in vivo activation of therapeutic drugs
US5462928A (en) *	1990-04-14	1995-10-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type IV
JPH04334357A (ja)	1991-05-02	1992-11-20	Fujirebio Inc	酵素阻害作用を有するアシル誘導体
CA2121369C (en)	1991-10-22	2003-04-29	William W. Bachovchin	Inhibitors of dipeptidyl-aminopeptidase type iv
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
IL106998A0 (en)	1992-09-17	1993-12-28	Univ Florida	Brain-enhanced delivery of neuroactive peptides by sequential metabolism
FR2696740B1 (fr)	1992-10-13	1994-12-30	Dospharma Sa	Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
WO1995011689A1 (en)	1993-10-29	1995-05-04	Trustees Of Tufts College	Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5543396A (en)	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en)	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
DE122010000020I1 (de) †	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
WO1997045117A1 (en)	1996-05-29	1997-12-04	Prototek, Inc.	Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5827898A (en) *	1996-10-07	1998-10-27	Shaman Pharmaceuticals, Inc.	Use of bisphenolic compounds to treat type II diabetes
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
AR016751A1 (es)	1996-11-22	2001-08-01	Athena Neurosciences Inc	Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
US6001155A (en)	1997-03-17	1999-12-14	Pease; John R.	Polyphasic pressurized homogenizer
EP2583675A1 (de)	1998-02-02	2013-04-24	Trustees Of Tufts College	Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus
JP2002506075A (ja)	1998-03-09	2002-02-26	フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ	セリンペプチダーゼ調節剤
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
AU4854999A (en)	1998-07-02	2000-01-24	Invitro Diagnostics, Inc.	Methods, compositions and apparatus for making nucleic acid molecules having a selected affinity to a target molecule
ATE251465T1 (de)	1998-07-31	2003-10-15	Novo Nordisk As	In-vitro stimulation von beta zellen vermehrung
DE19834591A1 (de)	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
WO2000053171A1 (en)	1999-03-05	2000-09-14	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1259246A2 (de)	2000-02-25	2002-11-27	Novo Nordisk A/S	Verwendung von dpp-iv inhibitoren zur behandlung von diabetes
US7064145B2 (en) *	2000-02-25	2006-06-20	Novo Nordisk A/S	Inhibition of beta cell degeneration
KR20080067009A (ko) *	2000-03-31	2008-07-17	프로시디온 리미티드	디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
US6890905B2 (en) *	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention

2001
- 2001-04-02 KR KR1020087014806A patent/KR20080067009A/ko not_active Ceased
- 2001-04-02 EP EP08172906.3A patent/EP2055302B1/de not_active Expired - Lifetime
- 2001-04-02 EP EP10179515.1A patent/EP2266665B1/de not_active Expired - Lifetime
- 2001-04-02 CN CN200910208114A patent/CN101690815A/zh active Pending
- 2001-04-02 PT PT81729063T patent/PT2055302E/pt unknown
- 2001-04-02 AT AT01927848T patent/ATE419036T1/de active
- 2001-04-02 RU RU2002129014/14A patent/RU2261096C2/ru active
- 2001-04-02 JP JP2001570251A patent/JP2003528135A/ja active Pending
- 2001-04-02 BR BR0109553-6A patent/BR0109553A/pt not_active Application Discontinuation
- 2001-04-02 AU AU2001254763A patent/AU2001254763A1/en not_active Abandoned
- 2001-04-02 PT PT101795151T patent/PT2266665T/pt unknown
- 2001-04-02 KR KR1020027013054A patent/KR20030019337A/ko not_active Ceased
- 2001-04-02 US US09/824,622 patent/US6500804B2/en not_active Expired - Fee Related
- 2001-04-02 ES ES01927848T patent/ES2320630T5/es not_active Expired - Lifetime
- 2001-04-02 HU HU0204459A patent/HU229042B1/hu unknown
- 2001-04-02 DK DK08172906.3T patent/DK2055302T3/da active
- 2001-04-02 ES ES08172906.3T patent/ES2525041T3/es not_active Expired - Lifetime
- 2001-04-02 PT PT01927848T patent/PT1283735E/pt unknown
- 2001-04-02 DE DE60137216T patent/DE60137216D1/de not_active Expired - Lifetime
- 2001-04-02 ES ES10179515.1T patent/ES2582376T3/es not_active Expired - Lifetime
- 2001-04-02 EP EP01927848A patent/EP1283735B2/de not_active Expired - Lifetime
- 2001-04-02 CZ CZ20023234A patent/CZ20023234A3/cs unknown
- 2001-04-02 IL IL15136801A patent/IL151368A0/xx active IP Right Grant
- 2001-04-02 CA CA002400226A patent/CA2400226C/en not_active Expired - Lifetime
- 2001-04-02 WO PCT/EP2001/003725 patent/WO2001072290A2/en not_active Ceased
- 2001-04-02 DK DK01927848.0T patent/DK1283735T4/da active
- 2001-04-02 CN CN01807402A patent/CN1420797A/zh active Pending
2002
- 2002-07-16 US US10/196,038 patent/US20020198242A1/en not_active Abandoned
- 2002-07-22 US US10/200,870 patent/US20030008905A1/en not_active Abandoned
- 2002-08-13 ZA ZA200206460A patent/ZA200206460B/en unknown
- 2002-09-27 NO NO20024643A patent/NO20024643L/no unknown
2003
- 2003-10-01 US US10/676,832 patent/US20050222221A1/en not_active Abandoned
2004
- 2004-08-02 US US10/910,176 patent/US20050014703A1/en not_active Abandoned
2006
- 2006-06-01 AU AU2006202344A patent/AU2006202344B2/en not_active Expired
2009
- 2009-03-12 CY CY20091100280T patent/CY1108872T1/el unknown

Also Published As

Publication number	Publication date
BR0109553A (pt)	2003-06-03
US20020198242A1 (en)	2002-12-26
WO2001072290A3 (en)	2002-03-14
CZ20023234A3 (cs)	2003-01-15
DK2055302T3 (da)	2014-10-27
ES2320630T3 (es)	2009-05-27
ZA200206460B (en)	2003-08-13
CY1108872T1 (el)	2014-07-02
US20010051646A1 (en)	2001-12-13
EP1283735B2 (de)	2012-10-24
IL151368A0 (en)	2003-04-10
AU2006202344B2 (en)	2009-01-08
AU2006202344A1 (en)	2006-06-22
CN101690815A (zh)	2010-04-07
JP2003528135A (ja)	2003-09-24
HU229042B1 (en)	2013-07-29
CA2400226A1 (en)	2001-10-04
EP1283735B1 (de)	2008-12-31
HK1051007A1 (en)	2003-07-18
HUP0204459A3 (en)	2006-01-30
WO2001072290A2 (en)	2001-10-04
PT2266665T (pt)	2016-07-07
US20050014703A1 (en)	2005-01-20
US20050222221A1 (en)	2005-10-06
DK1283735T3 (da)	2009-04-06
CN1420797A (zh)	2003-05-28
PT2055302E (pt)	2014-12-03
KR20080067009A (ko)	2008-07-17
US6500804B2 (en)	2002-12-31
EP1283735A2 (de)	2003-02-19
ES2320630T5 (es)	2013-03-12
US20030008905A1 (en)	2003-01-09
CA2400226C (en)	2007-01-02
EP2055302A1 (de)	2009-05-06
PT1283735E (pt)	2009-03-19
NO20024643D0 (no)	2002-09-27
DK1283735T4 (da)	2013-02-04
KR20030019337A (ko)	2003-03-06
EP2266665A1 (de)	2010-12-29
EP2266665B1 (de)	2016-05-11
HK1130015A1 (en)	2009-12-18
HUP0204459A2 (en)	2003-05-28
AU2001254763A1 (en)	2001-10-08
NO20024643L (no)	2002-11-05
ES2525041T3 (es)	2014-12-16
ES2582376T3 (es)	2016-09-12
DE60137216D1 (de)	2009-02-12
RU2261096C2 (ru)	2005-09-27
EP2055302B1 (de)	2014-09-10

Legal Events

Date

Code

Title

Description

2009-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1283735

Country of ref document: EP

Publication	Publication Date	Title
ATE419036T1 (de)	2009-01-15	Verbesserung der aktivität der inselzellen bei diabetes mellitus und dessen prävention
BR0111800A (pt)	2003-05-27	Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
CY1108769T1 (el)	2014-04-09	Αναστολεις της διπεπτιδυλικης πεπτιδασης iv για μειωση του ρυθμου της χρονιας αυξησης βαρους
WO2006001982A3 (en)	2006-08-17	Methods and compositions for treating neuropathies
WO2002038171A3 (en)	2003-04-24	METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
EP0643775A4 (de)	1995-12-27	Therapeutische zusammensetzungen.
WO2004012762A3 (en)	2004-06-17	Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US20170049865A1 (en)	2017-02-23	Proteolytic extract from bromelain for the treatment of connective tissue disorders
CO5280202A1 (es)	2003-05-30	Metodos de tratamiento y metodos de rastreo de farmacos
BG104062A (en)	2000-11-30	Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
WO2008078325A3 (en)	2009-04-16	A method of treating schizophrenia
WO2007105218A3 (en)	2008-12-31	Composition and method for brain tumor therapy
CY1117624T1 (el)	2017-04-26	Μεθοδος για τη βελτιωση της σηματοδοτησης νησιδιων στον σακχαρωδη διαβητη και την προληψη
IL162268A0 (en)	2005-11-20	Tempamine compositions and methods of use
MD3250G2 (ro)	2007-10-31	Metodă de tratament al sindromului cheroto-conjunctivitei sica
HK1151316A (en)	2012-01-27	Method for treating and preventing radiation damage using genetically modified mesenchymal stem cells